Is N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid? Is N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid safe for nursing mother and child? Does N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid extracts into breast milk? Does N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid has any long term or short term side effects on infants? Can N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid influence milk supply or can N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid decrease milk supply in lactating mothers?
N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid lactation summary
- DrLact safety Score for N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About N-((1-Allyl-2-pyrrolidinylmethyl)-5-sulfamoyl-2-veratramid usage in lactation
No data on transfer into breastmilk are available. Used in menopause. There is a possibility of galactorrhea by prolactin release stimulation. Withdrawn from the Europe market in 2005 because an increased risk of psychiatric damage.